SS Innovations International Inc

SS Innovations International Inc(SSII)股票分析

$3.480

+0.061 (+1.75%)收盤時

Loading chart…
High
3.600
Open
3.440
VWAP
3.51
Vol
12.54K
Mkt Cap
Low
3.440
Amount
43.96K
EV/EBITDA, TTM
-60.60

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.

AI analysis of SS Innovations International Inc (SSII)

buy

SS Innovations International Inc (SSII) appears to be a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $3.48, significantly below the analyst price target of $7, suggesting a potential upside of approximately 101%. Additionally, the company has shown a gross margin of 48.46% in Q2 2026, indicating strong profitability potential as it scales operations. However, it is important to note the risk of continued net losses, with a net income of -2,661,350 USD in Q2 2026, which could impact financial stability if not addressed.

估值指標

The current forward P/E ratio for SS Innovations International Inc (SSII) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-9.33
Current EV/EBITDA
-60.60
高估
7.96
低估
-26.62

Forward P/S

Overvalued
5Y Average P/S
2.48
Current P/S
8.99
高估
6.80
低估
-1.83

Alphio AI Price Scenarios for SSII

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SSII

$8.47

情境價格

B

Base

Base · 50%SSII

$7.13

情境價格

B

Bear

Bear · 25%SSII

$6.18

情境價格

事件時間軸

2026-07-14 (ET)

09:00:00

SS Innovations Appoints Sarah Romano as CFO

2026-05-05 (ET)

09:00:00

SS Innovations Surpasses 10,500 Cumulative Surgeries

2026-05-01 (ET)

16:30:00

SS Innovations Files to Sell 5.02M Shares of Common Stock

16:30:00

SS Innovations Files $150M Mixed Securities Shelf

2026-03-30 (ET)

09:30:00

SS Innovations Receives Regulatory Approval for SSi Mantra Surgical Robotic System

資訊

SSII FAQ — answered by Alphio AI

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. It operates in the Healthcare sector.

SS Innovations International Inc (SSII) appears to be a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $3.48, significantly below the analyst price target of $7, suggesting a potential upside of approximately 101%. Additionally, the company has shown a gross margin of 48.46% in Q2 2026, indicating strong profitability potential as it scales operations. However, it is important to note the risk of continued net losses, with a net income of -2,661,350 USD in Q2 2026, which could impact financial stability if not addressed.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始